CanBas Co., Ltd. engages in pharmaceutical business. It focuses on the research and development of anti-cancer agent, drugs, and technologies which has minor impact on normal cell. Its technologies include drugs for the G2 check point and a screening system to find selective abrogates of the G2 check point. The company was founded by Takumi Kawabe and Masashi Suganuma on January 18, 2000 and is headquartered in Numazu, Japan.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company